REQUEST A DEMO
Total
USD $0.00
Search more companies

Lek D.d. (Slovenia)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Lek D.d. Profile Updated: November 04, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Lek is a pharmaceutical company specializing in the development and production of antibiotic drugs, pain relief medications, probiotics, and dietary supplements. Lek is a provider of similar biological drugs and operates in the pharmaceutical industry. The company claims to have a strong presence in the market and offers solutions for various health conditions.

Headquarters
57 Verovshkova Street
Ljubljana-Lek; Postal Code: 1526

Contact Details: Purchase the Lek D.d. report to view the information.

Website: http://www.lek.si

Basic Information
Total Employees:
Purchase the Lek D.d. report to view the information.
Registered Capital:
Purchase the Lek D.d. report to view the information.
Financial Auditors:
Purchase the Lek D.d. report to view the information.
Incorporation Date:
January 12, 2026
Key Executives
Purchase this report to view the information.
Chairman of the Board of Directors
Purchase this report to view the information.
Internal Member of Board of Directors
Purchase this report to view the information.
Executive Manager
Purchase this report to view the information.
Executive Manager
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Doo Lek-ns Novi Sad - U Likvidaciji (Serbia)
100%
Sandoz D.d.
100%
Chnl D.o.o.
74.5%
Company Performance
Financial values in the chart are available after Lek D.d. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
-4.93%
Total operating revenue
-4.73%
Operating profit (EBIT)
-12.08%
EBITDA
-21.49%
Net Profit (Loss) for the Period
-11.3%
Total Assets
10.9%
Total Equity
14.61%
Operating Profit Margin (ROS)
-0.56%
Net Profit Margin
-0.43%
Return on Equity (ROE)
-3.76%
Debt/Equity
-11.44%
Quick Ratio
-0.05%
Cash Ratio
0.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?